Abnormal expression of p-ATM/CHK2 in nasal extranodal NK/T cell lymphoma, nasal type, is correlated with poor prognosis.

Abstract

AIMS:

The aim of this study is to investigate the expression profiles of cell cycle related proteins in nasal extranodal NK/T cell lymphoma, nasal type (ENKTCL).

METHODS:

The expression profiles of cell cycle related proteins were assessed with a cell cycle antibody array and validated by immunohistochemistry. Correlations between the expression levels of proteins and clinical outcomes of patients with nasal ENKTCL were evaluated.

RESULTS:

The expression of full length ataxia telangiectasia mutated (ATM) in nasal ENKTCL significantly decreased compared with that in nasal benign lymphoid proliferative disease (NBLPD), but the expression levels of p-ATM, CHK2 and RAD51 significantly increased in nasal ENKTCL compared with that in NBLPD. Kaplan-Meier analysis showed that the expression levels of p-ATM and CHK2 in nasal ENKTCL were inversely related to overall survival (p=0.011 and p=0.025, respectively).

CONCLUSION:

Abnormalities in the ATM pathway may play a crucial role in the oncogenesis and chemoradiotherapy resistance of nasal ENKTCL.

• Authors: Qiurong Ye, Huiling Chen, Zonghua Wen, Wenwen Guo, Yongta Huang, Xianglan Mo
• Journal: Journal of clinical pathology (J Clin Pathol) Vol. 74 Issue 4 Pg. 223-227 (Apr 2021) ISSN: 1472-4146 [Electronic] England
• PMID: 32220941 (Publication Type: Journal Article)
• Copyright: © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Biomarkers, Tumor
• Checkpoint Kinase 2
• ATM protein, human
• Ataxia Telangiectasia Mutated Proteins
• CHEK2 protein, human
• RAD51 protein, human
• Rad51 Recombinase

Topics

• Ataxia Telangiectasia Mutated Proteins (analysis)
• Biomarkers, Tumor (analysis)
• Cell Proliferation
• Checkpoint Kinase 2 (analysis)
• Drug Resistance, Neoplasm
• Humans
• Immunohistochemistry
• Lymphoma, Extranodal NK-T-Cell (enzymology, mortality, pathology, therapy)
• Neoplasm Grading
• Phosphorylation
• Rad51 Recombinase (analysis)
• Radiation Tolerance
• Risk Factors
• Time Factors
• Treatment Outcome
• Up-Regulation